News

Expanding the Clinical Impact of Molecular Testing in Pediatric and AYA Cancers

November 20, 2026 By Meg Barbor 6 min read
Share Share via Email Share on Facebook Share on LinkedIn Share on X

New consensus recommendations aim to standardize molecular profiling for children with solid tumors, addressing gaps in testing guidance for rare pediatric cancers, according to Alanna J. Church, MD, Associate Director of the Laboratory for Molecular Pediatric Pathology at Boston Children's Hospital and Dana-Farber Cancer Institute. Dr. Church is also Assistant Professor of Pathology at Harvard Medical School.

At the 2026 Association for Molecular Pathology (AMP) Annual Meeting & Expo in Seattle, Dr. Church discussed the recommendations as part of a broader presentation on molecular testing in pediatric and adolescent and young adult (AYA) cancers. She also reviewed emerging applications of circulating tumor DNA (ctDNA) testing and efforts to improve how genomic findings are communicated to patients and families.

New SPROUT Testing Recommendations

The Somatic Profiling for Pediatric Cancer: Refining Our Understanding and Treatment (SPROUT) Working Group developed consensus recommendations to help clinicians determine which molecular tests to order for children with solid tumors. Published online in Clinical Cancer Research on November 11, 2026, the recommendations were informed by a literature review that screened 361 articles and identified 41 studies for detailed evaluation.¹

The group recommends DNA-based next-generation sequencing (NGS) for all children with newly diagnosed solid tumors. RNA sequencing is recommended for tumors in which gene fusions are common, when the diagnosis is unclear, or when no driver alteration has been identified. DNA methylation profiling is also recommended for children with central nervous system tumors.

The group issued strong recommendations for all three testing approaches, citing a high level of certainty in the supporting evidence.

At relapse or recurrence, the SPROUT Working Group continues to strongly recommend DNA-based NGS, although the certainty of evidence is moderate. Repeat RNA sequencing receives a conditional recommendation, also with moderate certainty of evidence, because gene fusions often remain stable between diagnosis and recurrence.

Among the studies supporting the SPROUT recommendations was the Genomic Assessment Informs Novel Therapy (GAIN) Consortium study, which Dr. Church helped lead. In the multicenter study, 298 of 345 pediatric and AYA patients (86%) had at least one genomic alteration with potential clinical significance.²

Molecular profiling identified findings with diagnostic significance in 61% of patients, prognostic significance in 16%, and therapeutic significance in 65%, with some patients having findings in more than one category. Although many patients had potentially actionable alterations, only 29 received matched targeted therapy, and 24% of those patients experienced an objective response or durable clinical benefit.

Gene fusions were especially important, both for establishing diagnoses and identifying potential therapeutic targets. “A good take-home point is to always remember fusions in your pediatric cancer patients,” Dr. Church said.

She also presented clinical examples included in the SPROUT recommendations that illustrated how molecular testing can influence patient care. In one, RNA sequencing identified a CITED2::VGLL2 fusion in a newborn with sarcoma, establishing a diagnosis of spindle cell rhabdomyosarcoma and helping the care team avoid radiation therapy. In another, germline testing identified a TP53 mutation associated with familial Li-Fraumeni syndrome in an 11-year-old girl, providing information relevant to her family.

Advances in Pediatric ctDNA Testing

Beyond the SPROUT recommendations, Dr. Church discussed emerging applications of ctDNA testing in pediatric cancers, including recent findings in Ewing sarcoma.

In a study published in the Journal of Clinical Oncology, investigators evaluated ctDNA in 395 patients with Ewing sarcoma, including 140 with localized disease and 255 with metastatic disease.³ Higher pretreatment ctDNA levels were associated with poorer outcomes in both groups.

Among 35 patients with metastatic disease who underwent testing before the second chemotherapy cycle, those with ctDNA levels of at least 0.5% had a 2-year event-free survival rate of 5.3%, compared with 63% among those with lower levels (P < .001).

By combining ctDNA measurements with clinical and genomic factors, the investigators identified patients with relatively favorable prognoses, even among those with metastatic disease. Patients with localized disease, low ctDNA levels, smaller tumors, and favorable genomic characteristics experienced no events during follow-up. Among patients with metastatic disease confined to the lungs, those with low ctDNA levels and no STAG2 or TP53 mutations had a 2-year event-free survival rate of 83%.

Although ctDNA helped identify patients at greater risk of poor outcomes, further trials are needed to determine whether using these results to guide treatment decisions can improve survival.

Dr. Church's team is now working to bring a pediatric-specific ctDNA assay called BrightSeq Pulse into clinical practice. The assay combines a 237-gene cell-free DNA panel, including 19 fusion targets, with ultra-low-pass whole-genome sequencing to detect alterations commonly found in pediatric cancers. The test is undergoing analytical validation using plasma and cerebrospinal fluid samples, with a clinical launch planned for spring 2027.

The team plans to make the assay electronically orderable, with results returned through the electronic health record. Its clinical utility will also be studied in the CLARITY trial at Boston Children's Hospital, and the investigators hope to incorporate the assay into upcoming Children's Oncology Group studies.

Communicating Genomic Findings

Beyond developing new molecular tests, Dr. Church has also been working to improve how patients and families receive and understand their genomic results.

Through the Count Me In initiative, her team partners with patients with osteosarcoma and leiomyosarcoma to conduct genomic research and return results directly to participants. Patients, survivors, caregivers, clinicians, and research staff helped redesign how sequencing findings are communicated. Their feedback led to reports that begin with plain-language summaries, explain genetic alterations individually, and provide clearer information about uncertainty and the limitations of research testing.

She said the experience has influenced how she writes reports in her clinical practice, particularly when explaining prognosis or findings that do not have an immediate treatment implication.

Barriers to Testing and Reimbursement

According to Dr. Church, making molecular testing more accessible also requires addressing the practical challenges of implementing it. Laboratories need tests that detect alterations common in childhood cancers, as well as specialized expertise to interpret the results. Consent procedures must also take into account patients' ages, their ability to participate in medical decisions, and the involvement of parents or guardians.

Insurance reimbursement remains another obstacle, especially for rare diagnoses and emerging technologies. She said the SPROUT recommendations could help clinicians and laboratories advocate for coverage, although guidelines alone will not resolve reimbursement barriers.

Dr. Church is now developing research to examine which patients receive molecular testing, how tests are ordered, and whether findings affect care, along with patterns in insurance coverage and denials. She said addressing these gaps is part of her broader mission: “Every child facing a cancer diagnosis gets the right molecular testing to improve their care and their life.”

DISCLOSURES

Dr. Church reported no conflicts of interest.

REFERENCES

1.              Gestrich C, Furtado LV, Biegel J, et al: SPROUT guidelines for molecular profiling for children with solid tumors: A consensus recommendation from the American Association for Cancer Research. Clin Cancer Res. Published online November 11, 2026.

2.              Church AJ, Corson LB, Kao PC, et al: Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nat Med 28:1581-1589, 2022

3.              Shulman DS, Klega K, Chen N, et al: Circulating tumor DNA profiling defines risk classification in patients with Ewing sarcoma: A report from the Children's Oncology Group and the LEOPARD study. J Clin Oncol. Published online September 15, 2026.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.